Details for Patent: 6,992,110
✉ Email this page to a colleague
Title: | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Abstract: | The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed. |
Inventor(s): | Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA) |
Assignee: | Cypress Bioscience, Inc. (San Diego, CA) |
Filing Date: | Jul 18, 2003 |
Application Number: | 10/623,378 |
Claims: | 1. A method of treating pain in an animal subject, comprising administering to an animal subject suffering from pain, an effective amount of milnacipran, or a pharmaceutically acceptable salt thereof, alone or in combination with a compound that is not phenylalanine, tyrosine or tryptophan. 2. The method according to claim 1, wherein the compound is adjunctively administered with antidepressants, analgesics, muscle relaxants, anorectics, stimulants, antiepileptic drugs, sedatives, or hypnotics. 3. The method according to claim 1, wherein the compound is adjunctively administered with neurontin, pregabalin, pramipexole, 1-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, a tricyclic antidepressant, codeine, carbamazepine, sibutramine, valium, or trazodone. 4. The method according to claim 1, wherein the animal subject is human. 5. The method according to claim 1, wherein the amount administered is from about 25 mg to about 400 mg per day. 6. The method according to claim 1, wherein the compound is formulated in a sustained release dosage formulation. |